Regenxbio Inc. (RGNX) Trading Down 1.7%
Regenxbio Inc. (NASDAQ:RGNX) shares traded down 1.7% during mid-day trading on Monday . The company traded as low as $7.91 and last traded at $8.00, with a volume of 65,895 shares traded. The stock had previously closed at $8.14.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Morgan Stanley boosted their price target on shares of Regenxbio from $34.00 to $36.00 in a research report on Friday, April 8th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $33.00 target price on shares of Regenxbio in a research report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Regenxbio has a consensus rating of “Buy” and an average price target of $28.35.
The stock’s 50-day moving average price is $10.27 and its 200-day moving average price is $11.88. The company’s market cap is $200.70 million.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.01. Analysts expect that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.
In other news, insider Fmr Llc sold 10,570 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $9.94, for a total value of $105,065.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.